Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xenetic Biosciences (XBIO) Operating Expenses (2023 - 2025)

Xenetic Biosciences' Operating Expenses history spans 7 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 20.52% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $5.8 million, down 13.33%, while the annual FY2025 figure was $5.8 million, 13.33% down from the prior year.
  • Operating Expenses reached $1.4 million in Q4 2025 per XBIO's latest filing, down from $1.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $2.1 million in Q2 2024 to a low of $1.1 million in Q3 2024.
  • Average Operating Expenses over 3 years is $1.6 million, with a median of $1.7 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: plummeted 36.64% in 2024, then surged 41.12% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $1.9 million in 2023, then decreased by 9.32% to $1.7 million in 2024, then dropped by 20.52% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for XBIO's Operating Expenses are $1.4 million (Q4 2025), $1.6 million (Q3 2025), and $1.3 million (Q2 2025).